Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer According to Tumor-vessel Relationship and CA 19-9 Levels

ID
Name
NAT in resectable PDAC
Description
An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer
Trial arms
Trial start
2007-01-01
Estimated PCD
2021-12-01
Trial end
2021-12-01
Status
Completed
Treatment
Neoadjuvant treatment
Intravenous gemcitabine-based combination regimens or FOLFIRINOX were included in NAC.
Arms:
borderline resectable PDAC with PV/SMV contact >180° and without arterial involvement (BR-V), resectable PDAC with contact PV/SMV of ≤180° (R-contact), resectable PDAC with no contact to major vessels (R-no contact)
Size
1132
Primary endpoint
Overall survival
From the date when biopsy results came out until the date of death from any cause or the date of the last visit, whichever came first, assessed up to 60 months
Eligibility criteria
Inclusion Criteria: * Patients diagnosed with resectable or borderline resectable pancreatic ductal adenocarcinoma (PDAC) * Between January 2007 and June 2021 at Seoul National University Hospital Exclusion Criteria: * Patients who had borderline resectable PDAC with arterial invasion * Patients who received chemotherapy as initial treatment and did not undergo surgery * Incomplete follow-up data for analysis
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_CONTROL', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 1132, 'type': 'ACTUAL'}}
Updated at
2023-11-13

1 organization

1 product

2 indications

Organization
Seoul National University Hospital
Product
Neoadjuvant treatment
Indication
Pancreatic Cancer
Indication
Neoadjuvant